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Abstract The oncogenic capabilities of the cell cycle protein
cyclin D1 have long been established in a breast cancer
setting. The CCND1 gene is amplified in up to 15 % of breast
tumors, with overexpression of its corresponding protein
found in up to 50 % of cases. While gene amplification is
consistently associated with reduced patient survival times
and treatment resistance, repeated attempts to clarify the prog-
nostic and predictive impact of the cyclin D1 protein in breast
cancer have yielded contrasting results. Here, we recommend
that any examination of cyclin D1 in a patient cohort should
begin by determining CCND1 copy number, with subsequent
removal and separate analysis of amplified cases. Next, the
remaining tumors should be examined for cyclin D1 protein
expression in the context of well-defined breast cancer sub-
groups. Only in this manner can the true clinical value of
cyclin D1 be fully elucidated.
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Background
The cyclin family of cell cycle regulatory proteins coalesces
with their binding partners, the cyclin-dependent kinases
(CDKs), to strictly govern the incremental steps leading to
mammalian cell division. Consecutive expression of cyclins
D, E, A, and B are essential for the successful transition of a
cell through the G1, S, and G2/M phases of cell cycle, respec-
tively. As such, perturbations in these proteins, resulting in
uncontrolled proliferation, can be considered an oncogenic
event. The 34 kDa G1 to S-phase transition marker cyclin
D1 represents the best studied cell cycle protein and has been
well established as a human oncogene in a breast cancer
setting. Upon complex formation with CDK 4/6, cyclin D1
phosphorylates and inactivates the retinoblastoma (Rb) pro-
tein, resulting in the release of E2F transcription factors and
progression of cell cycle. While the protein’s biological role
would appear straightforward, studies examining the relation-
ship between cyclin D1 and clinical outcome of breast cancer
patients have yielded inconsistent findings. Here, we explore
the potential shortcomings of how cyclin D1 is currently
analyzed and recommend improvements, with the aim of
enhancing its clinical utility.
The Need to Resolve Conflicting Results
Cyclin D1 has remained a putative prognostic and predictive
biomarker in breast cancer for well over a decade. However,
repeated clinical analyses producing conflicting results have
left this promising marker teetering on the edge of consign-
ment to the “never quite made it” file. This would be a harsh
injustice, for if we take a step back and delve into the infor-
mation we have garnered thus far, it is readily apparent that its
potential has been limited only by our misinterpretation of
cyclin D1 amplification and protein expression data. To be
more precise, we have failed to consistently separate these two
very different biological phenomena when determining the
relevance of cyclin D1 in a breast cancer setting.
Amplification of the cyclin D1 gene (CCND1) occurs in
15% of primary estrogen receptor (ER) positive breast cancers,
while overexpression of the protein is found in 50 % of cases.
These figures are well established and indicate that mechanisms
other than gene amplification are responsible for dysregulation
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of the protein. The vast majority of breast tumors bearing
CCND1 amplification are readily defined as ER positive, are
luminal B by gene expression analysis, and overexpress cyclin
D1 protein; most notably, patients with CCND1 amplified
tumors show reduced survival times and associations to treat-
ment resistance. Remarkably, this picture of dynamic clinical
utility in both a prognostic and predictive setting has been
blurred by conflicting assessments of the relationship between
cyclin D1 protein levels and clinicopathological parameters.
Overexpression of cyclin D1 protein has been linked with
both positive (most likely due to associations with ER +
tumors) and negative breast cancer prognosis. However, the
relevancy of these findings is often ambiguous, owing to
antibody disparities and low patient numbers, resulting in
underpowered conclusions. Further confusing matters, tumors
high in cyclin D1 protein have been linked with resistance to
endocrine therapy and shorter recurrence-free survival of
breast cancer patients. These uncertain results directly contrast
the consistent message provided by CCND1 amplified
tumors. This highlights the necessity of separating patients
with amplification of the gene for independent analysis before
relating expression of cyclin D1 protein to clinicopathological
data. Given that the vast majority ofCCND1 amplified tumors
overexpress cyclin D1 protein and have poor prognosis, they
represent a separate entity and should be treated as such. In
any analysis examining the relevance of cyclin D1 protein in
breast cancer, failing to remove the CCND1 amplified cases
biases the cyclin D1 overexpressed group by artificially in-
flating the number of cyclin D1 “high” tumors with a worse
clinical outcome. The significance of this should not be under-
estimated; it is not common practice to remove amplified
cases before conducting cyclin D1 protein analysis. Thus,
we cannot say with any certainty how the protein influen-
ces patient survival and response to treatment.
Proceeding in this manner will allow us to determine the
protein’s true relationship to breast cancer outcome and
could even alter how we interpret its expression. For in-
stance, instead of thinking of cyclin D1 as a cell cycle
marker, it could be thought of as an indicator for an intact
and functional ER. When bound to estrogen, ER upregulates
cyclin D1 mRNA and protein expression, resulting in nor-
mal to elevated levels of cyclin D1 protein in ER + tumors.
Additionally, cyclin D1 has the ability to upregulate ER in
the absence of estrogen. This evidence implies that low
expression of the protein in ER + tumors could be inter-
preted as a loss of control over ER signaling and as an
oncogenic indicator. However, this concept is somewhat
obscured by the ability of pathways including MAP kinase
to stimulate cyclin D1 transcription independently of ER.
Nevertheless, the fact remains that tumors associated with
ER positivity, specifically those in the luminal breast cancer
subgroups, tend to express more cyclin D1 on the mRNA
and protein levels than do those that are ER negative.
Similar pursuits for functions of cyclin D1 outside of its
classical cell cycle role have led to the elucidation of its asso-
ciations to epithelial-to-mesenchymal transition, to cell inva-
sion/migration, and as a promoter of Notch1 expression. These
studies not only highlight why we should refrain from casting
cyclin D1 as a mere cell cycle regulator, but also provide
evidence of the protein’s complex interactions. Indeed, given
these diverse capabilities, it should come as little surprise that
such conflicting results have been observed when its protein
levels have been related to patient outcome. This makes the
argument for analyzing gene amplified cases separately all the
more relevant, and furthermore, if the biological interplay of the
protein is so diverse, dividing tumors into clinically relevant
subgroups should form an intrinsic part of any analysis.
Subgroup Analysis of Cyclin D1 Protein Expression
Tumor pathology and gene expression profiling has taught us
to view breast cancer as a complex, heterogeneous disease, but
one that can be separated into biologically relevant subgroups
using the clinical biomarkers ER, progesterone receptor, hu-
man epidermal growth factor receptor 2 (HER2), and Ki67. In
addition to differences in underlying biology, patients in these
subgroups also display diverging responses to tumor therapy,
sites of tumor relapse, and survival time. Given these broad
differences, it is unlikely that cyclin D1 protein has the same
clinical relevance in all breast cancer subtypes. Consider the
case of a luminal B breast tumor: This subgroup is strongly
ER positive and displays elevated levels of cyclin D1 protein.
In contrast, the basal subgroup of breast cancer is typified by
its ER negativity and low cyclin D1 expression. On the basis
of this, low expression of cyclin D1 in a luminal tumor would
represent a deviation from the normal and potentially would
indicate disrupted ER signaling; but in a basal tumor, the
opposite is true, and high expression would be considered an
aberration. Since most breast cancer cohorts contain approx-
imately 70 % luminal tumors, the relevance of cyclin D1 in
smaller subgroups such as basal tumors is lost, demonstrating
why subgroup analysis is so important.
Finally, an alternate strategy in the analysis of cyclin D1
could be to group tumors on the basis of how the protein
relates to a cell proliferation, using a marker such as Ki67.
In its fundamental role, cyclin D1 indicates progression of
the cell cycle and acts as a sign that a cell population is
actively proliferating. However, its cyclic nature prevents its
use as a bona fide proliferation marker, a task better suited to
the routinely employed Ki67 protein. Notably, cyclin D1 has
been both positively and negatively correlated to Ki67 ex-
pression, raising an interesting question worthy of explor-
atory analysis: Can the relationship between Ki67 and
cyclin D1 predict clinical outcome and potentially indicate
treatment resistance? For example, if cyclin D1 protein and
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Ki67 are both elevated in a tumor, does this denote an intact
proliferative cycle and a better response to therapy? This
relationship is rarely considered in cyclin D1 protein analy-
sis and certainly never after having removed CCND1 am-
plified cases from the equation first.
Summary and Recommendations
Clearly, if cyclin D1 is to succeed as a prognostic or treat-
ment predictive biomarker in breast cancer, a stronger se-
lection criterion must be imposed on tumor samples to
achieve consistent results. If researchers persist in analyzing
cyclin D1 protein expression without first removing CCND1
amplified cases, we will continue to see conflicting, variable
results, much to the demise of this promising biomarker. We
therefore recommend that any examination of cyclin D1 in a
clinical material must begin with a determination of CCND1
copy number and subsequent independent analysis of any
amplified cases. Next, protein expression of the remaining
samples should be analyzed in the context of clinically
relevant subgroups by separating tumors based on ER, PR,
HER2, and Ki67 expression. While this may result in few
cases in each subgroup, it is preferable to the alternative of
trying to apply a single biomarker to range of diverse,
biologically distinct tumors. If these strategies are rigorously
applied, they will solidify the importance of CCND1 ampli-
fication as a clinical marker and will allow us to determine
the relevance of aberrant cyclin D1 protein expression in
breast tumors.
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